Transparency issues weaken public trust in pharma

10/30/2013 |

People's confidence in drugs and research is compromised by high costs for treatments and a lack of access to trial data and information on financial relationships, writes Jill Wechsler in this blog post. PhRMA and the European Federation of Pharmaceutical Industries and Associations have launched voluntary data sharing efforts. Drugmakers must focus on demonstrating clinical value in real-world trials, and be ready to talk about the results, Wechsler writes.

View Full Article in: